Back to search
FDAFDA · Food and drugs·Recall number D-1247-2014

Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK Drive, Moon Township, PA 15108. UPC: 0-03-0766-1480-30-2.

Published April 30, 2014 · Recall initiated: February 20, 2014

Summary

FDA records drug Class III recall D-1247-2014, published April 30, 2014 and initiated February 20, 2014. Recalling firm: GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline; Status: Terminated; Reported quantity: 150 cases; Lot: Lot #13L05N, Expiry: 8/15. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
Distributor
U.S. Nationwide
Lot
Lot #13L05N, Expiry: 8/15
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK Drive, Moon Township, PA 15108. UPC: 0-03-0766-1480-30-2. recalled?

Yes. FDA published recall D-1247-2014 on April 30, 2014. Reported hazard: Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

What should I do if I have this product?

Voluntary: Firm initiated · Letter